William Mariner Greenman Sells 71,086 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) CEO William Mariner Greenman sold 71,086 shares of the company’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $1.45, for a total value of $103,074.70. Following the completion of the sale, the chief executive officer now directly owns 4,238,672 shares of the company’s stock, valued at approximately $6,146,074.40. This trade represents a 1.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

William Mariner Greenman also recently made the following trade(s):

• On Friday, March 7th, William Mariner Greenman sold 60,984 shares of Cerus stock. The shares were sold at an average price of $1.50, for a total value of $91,476.00.
• On Tuesday, March 4th, William Mariner Greenman sold 23,023 shares of Cerus stock. The shares were sold at an average price of $1.55, for a total value of $35,685.65.

Cerus Price Performance

NASDAQ CERS opened at $1.43 on Wednesday. The business has a 50 day simple moving average of $1.72 and a 200 day simple moving average of $1.75. Cerus Co. has a 52-week low of $1.38 and a 52-week high of $2.54. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.92 and a current ratio of 2.59. The stock has a market cap of $265.68 million, a price-to-earnings ratio of -13.00 and a beta of 1.56.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.01). Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%. The business had revenue of $50.81 million during the quarter, compared to analysts’ expectations of $50.81 million. Analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cerus

Large investors have recently bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new position in Cerus during the 4th quarter worth approximately $25,000. Rockport Wealth LLC acquired a new position in Cerus during the 4th quarter worth approximately $25,000. Cibc World Markets Corp acquired a new position in Cerus during the 4th quarter worth approximately $26,000. R Squared Ltd acquired a new position in Cerus during the 4th quarter worth approximately $29,000. Finally, Virtu Financial LLC acquired a new position in Cerus during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 78.37% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price target on shares of Cerus in a research note on Friday, February 21st.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.